10621670

=> d his

(FILE 'HOME' ENTERED AT 16:56:52 ON 06 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:57:14 ON 06 FEB 2004

FILE 'CAPLUS' ENTERED AT 16:58:01 ON 06 FEB 2004

FILE 'REGISTRY' ENTERED AT 16:58:19 ON 06 FEB 2004
E DESLORATADINE/CN
L1 1 S E3

FILE 'CAPLUS' ENTERED AT 16:59:11 ON 06 FEB 2004
L2 228 S L1
L3 5 S L2 AND FUMAR?
L4 2 S L2 AND POLYMORPH?

=> DIS L4 1 TI

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
TI **Polymorphs** of descarbonylethoxyloratadine

=> DIS L4 2 TI

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
TI **Polymorphs** of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine

=> d bib abs hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:35358 CAPLUS
DN 138:78570
TI **Polymorphs** of descarbonylethoxyloratadine
IN Schumacher, Doris P.; Lee, Junning; Rogers, Lawrence R.; Eckhart, Charles G.; Sawant, Naneshwar S.; Mitchell, Michael B.
PA Schering Corporation, USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6506767	B1	20030114	US 1998-108689	19980701
PRAI	US 1997-51547P	P	19970702		

AB Crystalline **polymorphs** of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (descarbonylethoxyloratadine), pharmaceutical compns. containing such **polymorphs**, and methods of using such **polymorphs** to treat allergic reactions in mammals, including humans, are disclosed.
IT **100643-71-8P**
RL: IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of **polymorphs** of antiallergic descarbonylethoxyloratadine)
RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:48718 CAPLUS
DN 130:115013
TI **Polymorphs** of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
IN Schumacher, Doris P.; Lee, Junning; Rogers, Lawrence R.; Eckhart, Charles G.; Sawant, Naneshwar S.; Mitchell, Michael B.
PA Schering Corporation, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901450	A1	19990114	WO 1998-US13433	19980701
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9805783	A	19990119	ZA 1998-5783	19980701
	AU 9882710	A1	19990125	AU 1998-82710	19980701
	AU 734487	B2	20010614		
	EP 993455	A1	20000419	EP 1998-932930	19980701
	EP 993455	B1	20030502		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
	BR 9811658	A	20000905	BR 1998-11658	19980701
	NZ 501417	A	20001027	NZ 1998-501417	19980701
	JP 2002507991	T2	20020312	JP 1999-507265	19980701
	RU 2197485	C2	20030127	RU 2000-102669	19980701
	AT 239010	E	20030515	AT 1998-932930	19980701
	NO 9906547	A	20000301	NO 1999-6547	19991229
PRAI	US 1997-886766	A	19970702		
	WO 1998-US13433	W	19980701		

AB Crystalline **polymorphs** of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (I), pharmaceutical compns. containing such **polymorphs**, and methods of using such **polymorphs** to treat allergic reactions in mammals such as man are disclosed. I **polymorph** form 1 was prepared by hydrolysis of ethanolic loratadine in presence of KOH and recrystn. from Me iso-Bu ketone. The **polymorph** form 1 was a white crystalline solid containing 100% form 1, with no detectable amount of form 2.
IT **100643-71-8P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**polymorphs** of descarbonyethoxyloratadine)
RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

10621670

=> d his

(FILE 'HOME' ENTERED AT 16:56:52 ON 06 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:57:14 ON 06 FEB 2004

FILE 'CAPLUS' ENTERED AT 16:58:01 ON 06 FEB 2004

FILE 'REGISTRY' ENTERED AT 16:58:19 ON 06 FEB 2004
E DESLORATADINE/CN
L1 1 S E3

FILE 'CAPLUS' ENTERED AT 16:59:11 ON 06 FEB 2004
L2 228 S L1
L3 5 S L2 AND FUMAR?

=> d 1-5 bib abs hitstr

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:988191 CAPLUS
DN 140:12688
TI Comparison of ketotifen **fumarate** ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial
AU Crampton, H. Jerome
CS Ophthalmic Research Associates, North Andover, MA, USA
SO Clinical Therapeutics (2003), 25(7), 1975-1987
CODEN: CLTHDG; ISSN: 0149-2918
PB Excerpta Medica, Inc.
DT Journal
LA English
AB Background: Ketotifen **fumarate** is a topical antiallergic combination mast-cell stabilizer and antihistamine indicated for the temporary prevention of ocular itching due to allergic conjunctivitis. Desloratadine is a systemic antihistamine indicated for the treatment of seasonal and perennial allergic rhinitis. Objective: The purpose of this study was to compare the efficacy of ketotifen 0.025% ophthalmic solution instilled in the eye, desloratadine 5-mg tablets taken orally, and their combination for prevention of the signs and symptoms of allergic rhinoconjunctivitis, as induced by the conjunctival allergen challenge (CAC) model. Methods: This was a randomized, double-masked, placebo- and active-controlled, single-center clin. trial. At visit 1, the dose of allergen necessary to elicit a qualifying allergic reaction was determined for subjects meeting the entry criteria. At visit 2, the allergen dose determined at visit 1 was confirmed, and all subjects who had a qualifying ocular and nasal allergic reaction were randomized to 1 of 3 treatment groups: ketotifen ophthalmic solution and placebo tablet, desloratadine tablet and placebo eyedrop, or ketotifen and desloratadine. Subjects were instructed to instill 1 drop into each eye twice daily and take 1 tablet with water once daily at the same time as the morning eyedrop for .apprx.4 wk. At visit 3, subjects brought in their medication and were given 1 drop of the eyedrop bilaterally and 1 tablet with water. Bilateral CAC was performed 2 h after administration of medication. Using standardized scales, subjects rated ocular itching at 3, 5, and 7 min after CAC; ocular tearing and eyelid swelling at 10, 15, and 20 min after CAC; and nasal signs and symptoms (sneezing, rhinorrhea and postnasal drip, pruritus, and nasal congestion) at 10, 20, 30, 40, and 50 min after CAC. The investigator graded ocular redness and chemosis at 10, 15, and 20 min after CAC. At all visits, subjects were offered an anti-allergy eyedrop to relieve any immediate ocular discomfort caused by CAC. Results: One hundred two subjects were screened-82 (55 women, 27 men; mean age, 42.8 yr [range, 21-70 yr]) were randomized to treatment, and 80 completed the study. Subjects in the group that received ketotifen (n = 27) and the group that received ketotifen with desloratadine (n = 26) had significantly lower mean itching scores compared with those in the group that received desloratadine alone (n = 27) at all time points ($P \leq 0.05$). Total ocular redness, calculated by summing the mean redness scores for each of the 3 vessel beds, was significantly lower in the ketotifen group than in the other treatment groups at most time points ($P \leq 0.05$). All treatments attenuated nasal symptoms; no statistically significant differences were noted between treatment groups, with the exception of the 50-min time point, at which combination treatment was significantly more effective than ketotifen alone ($P \leq 0.05$). The proportion of subjects who requested relief drops after CAC was significantly lower in both the ketotifen alone and combination treatment groups compared with the desloratadine alone group ($P = 0.004$). Conclusions: Ketotifen

ophthalmic solution significantly decreased the signs and symptoms of ocular and nasal allergic rhinoconjunctivitis. The addition of ketotifen to the oral desloratadine regimen improved the overall antiallergic efficacy of both medications.

IT **100643-71-8**, Desloratadine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison of efficacy of ketotifen **fumarate** ophthalmic solution alone, desloratadine alone, and their combination for inhibition of signs and symptoms of seasonal allergic rhinoconjunctivitis in conjunctival allergen challenge model)

RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:720795 CAPLUS
DN 138:280580
TI FDA new drug approvals in 2001
AU Zhao, Kang; He, Lan; Reiner, John
CS The College of Pharmaceuticals and Biotechnology, Tianjin University, Peop. Rep. China
SO Frontiers of Biotechnology & Pharmaceuticals (2002), 3, 400-413
CODEN: FBPRBL
PB Science Press New York Ltd.
DT Journal; General Review
LA English
AB A review covering the 24 new drugs approved by the Food and Drug Administration in the year 2001. Therapeutics are grouped according to the following coded areas: (A) agents affecting neurotransmitters and cytokines, (B) antiinflammatory agents, (C) hormone related agents, (D) anti-infectious agents, and (E) miscellaneous agents. A synopsis for each drug includes a brief description of its medical utility, a mechanism of action if known, a chemical structure, and a pathway for its synthesis.

IT **100643-71-8P**, Desloratadine
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(FDA new drug approvals in 2001)

RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:503329 CAPLUS
DN 137:68175

10621670

TI Texture masked particles coated with a film-forming polymer and an anti-grit agent
IN Parikh, Narendra; McTeigue, Daniel; Wynn, David W.; Pillai, Ravivaj S.
PA McNeil-PPC, Inc., USA
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1219291	A1	20020703	EP 2001-310751	20011221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002119196	A1	20020829	US 2000-745243	20001221
	AU 2001097361	A5	20020627	AU 2001-97361	20011221
	CN 1366878	A	20020904	CN 2001-145483	20011221
	JP 2002272817	A2	20020924	JP 2001-390445	20011221
	NZ 516341	A	20030829	NZ 2001-516341	20011221
	BR 2001006912	A	20030916	BR 2001-6912	20011221
PRAI	US 2000-745243	A	20001221		

AB Texture masked particles and chewable tablets made therefrom are disclosed. The texture masked particles are comprised of (i) a core containing an active ingredient, e.g. and antacid or non-steroidal anti-inflammatory agent, (ii) an optional first layer of a taste masking agent that substantially covers the core, and (iii) a texture masking coating layer on the surface of the core comprising a film-forming polymer and an anti-grit agent. A taste masked particles comprise (i) a core containing an active ingredient, and (ii) a taste masking agent composed of an enteric polymer and an insol. film-forming polymer. The particles may be produced into a tablet form, such as a chewable tablet, that provides for the immediate release of the active ingredient. For example, a texture masking coating solution was prepared by dispersing equal amount of hydroxypropyl Me cellulose and polyethylene glycol 800 together with acesulfame potassium (1% of solids) in a solvent comprising 77% ethanol and 23% water so that the solid materials represented 10% of the finished solution Then, Et cellulose-encapsulated acetaminophen (1000 g) was sprayed with the texture masking coating solution prepared so that the level of the texture masking coating materials was 7% by weight of the total finished texture masked coated particles. The resulting coated particles had an average diameter of 380 μ.

IT **100643-71-8**, Desloratadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(texture and taste masked particles coated with film-forming polymer and anti-grit agent)
RN 100643-71-8 CAPLUS
CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:353315 CAPLUS
DN 136:374833
TI Inhalant composition containing tiotropium salts and anti-histamines
IN Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague; Schmelzer, Christel
PA Boehringer Ingelheim Pharma Kg, Germany
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 6

10621670

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036163	A2	20020510	WO 2001-EP12510	20011023
	WO 2002036163	A3	20021212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10138272	A1	20030227	DE 2001-10138272	20010810
	US 2002151541	A1	20021017	US 2001-7182	20011019
	US 2002183292	A1	20021205	US 2001-86145	20011019
	AU 2002014030	A5	20020515	AU 2002-14030	20011023
	EP 1341538	A2	20030910	EP 2001-982446	20011023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002137764	A1	20020926	US 2001-40196	20011025
	US 2003181478	A1	20030925	US 2003-395777	20030324
PRAI	DE 2000-10054042	A	20001031		
	DE 2001-10138272	A	20010810		
	US 2000-253613P	P	20001128		
	DE 2000-10062712	A	20001215		
	US 2000-257220P	P	20001221		
	US 2001-314599P	P	20010824		
	WO 2001-EP12510	W	20011023		
	US 2001-40196	B1	20011025		

AB The invention relates to inhalant compns. based on tiotropium salts and anti-histamines, a method for their production and their use for treating respiratory illnesses, e.g. allergic and non-allergic rhinitis. Thus and inhalation powder contained per microcapsule (μg): tiotropium bromide 21.7; epinastine-hydrochloride 200; lactose 4778.3.

IT **100643-71-8**, Desloratadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalant composition containing tiotropium salts and anti-histamines)

RN 100643-71-8 CAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:635179 CAPLUS

DN 125:275664

TI 8-Chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidylidene]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine **fumarate** and its preparation and use as a PAF antagonist and antihistaminic

IN Carceller, Elena; Recasens, Nuria; Almansa, Carmen; Bartroli, Javier; Merlos, Manel; Giral, Marta

PA J. Uriach & Cia. S.A., Spain

SO Span., 11 pp.
CODEN: SPXXAD

DT Patent

LA Spanish

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ES 2087818	A1	19960716	ES 1993-2460	19931124
	ES 2087818	B1	19970316		
	NO 9404487	A	19950526	NO 1994-4487	19941123
PRAI	ES 1993-2460		19931124		

GI

10621670



I

AB The title salt I-**fumarate** is prepared for use as an antagonist of PAF (platelet activating factor) and an antihistaminic (no data). I-**fumarate** has improved hygroscopicity and light stability in comparison to I.3HCl or the free base I. For example, I was prepared from loratadine by a sequence of: hydrolytic removal of the N-ethoxycarbonyl group (84%), N-acylation with 5-methylnicotinic acid using DCC and HOBt (65%), and chlorination/reduction of the amide using POCl3 followed by NaBH4 (72%). Treatment of I with **fumaric** acid in EtOH gave 70% I-**fumarate**. When exposed to 98% humidity for 24 h, H2O contents were 5.7% for I, and 28.3% for I.3HCl, but only 0.29% for I-**fumarate**. Similarly, irradiation at 150 klx for 1 h reduced purities to 92.7% for I, to 74% for I.3HCl, but only to 99.2% for I. **fumarate**.

IT **100643-71-8P**, 8-Chloro-11-(4-piperidylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzocycloheptapyridine derivative **fumarate** salt as PAF antagonist and antihistaminic with improved properties)

RN 100643-71-8 CAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



=>